Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allergies
Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis
May 22nd, 2009
Fovea Pharmaceuticals announced positive results from its clinical proof-of-concept trial to assess the therapeutic effect of Prednisporin(TM) (FOV1101) in patients with persistent allergic conjunctivitis. Prednisporin(TM) had the same efficacy and a better safety profile (no increase in intra-ocular pressure) than PredForte(TM), a prescription drug with a 10 fold higher dose of prednisolone acetate, in patients treated for the signs and symptoms (itching and redness) of persistent ocular allergic inflammation. A one-week pre-treatment with Pataday(TM) (an anti-histamine) had negligible effect on these parameters in this patient population. The...
Source: Health Business Week (2009-05-22)
|
